Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia

The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from theLos Alamosdatabank

(2013) R. Alves et al.   JOURNAL OF VIRAL HEPATITIS

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy

(2012) I. Vicenti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

(2012) Doug J. Bartels et al.   JOURNAL OF VIROLOGY

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

(2011) Philip J. F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5

(2011) Sophie Vallet et al.   ANTIVIRAL THERAPY

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

(2011) Jean-Michel Pawlotsky   HEPATOLOGY

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

(2011) Stefan Zeuzem et al.   HEPATOLOGY

Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients

(2011) Hiroko Shindo et al.   Hepatology International

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients

(2011) P Trimoulet et al.   HIV MEDICINE

Hepatitis C virus resistance to protease inhibitors

(2011) Philippe Halfon et al.   JOURNAL OF HEPATOLOGY

Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA

(2011) A. M. Lam et al.   JOURNAL OF VIROLOGY

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

(2011) Philippe Halfon et al.   LIVER INTERNATIONAL

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

(2010) C. M. Lange et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection

(2009) Pierre L Beaulieu   EXPERT OPINION ON THERAPEUTIC PATENTS

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

(2008) A. Y. M. Howe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

(2008) S. Le Pogam et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES